• 14

• August

• 2023

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

LEARN MORE

• 11

• August

• 2023

The Secrets of Women Who Wake Up Looking Beautiful (Hint: It’s Not a Good Night’s Sleep)

LEARN MORE

• 08

• August

• 2023

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

LEARN MORE

• 01

• August

• 2023

Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

LEARN MORE

• 30

• June

• 2023

Revance Therapeutics pushes Botox ‘breakup’ in latest campaign for rival cosmetic drug

LEARN MORE

• 29

• June

• 2023

How RHA Fillers By Revance Adapt To Our Facial Dynamics

LEARN MORE